Table 4 Number of annual cases of each lesion attributable to HPV genotypes targeted by the 4-valent and 9-valent vaccines and associated costs
Lesion | Cases attributable to HPV 6/11/16/18 and associated costs | Cases attributable to HPV 6/11/16/18/31/33/45/52/58 and associated costs | Cases attributable to HPV 31/33/45/52/58 and associated costs (a) | |||
|---|---|---|---|---|---|---|
Number of annual cases | Costs (€ 2017) | Number of annual cases | Costs (€ 2017) | Number of annual cases | Costs (€ 2017) | |
Genital warts (b) | 49,251 | 51.04 Mill € | 49,251 | 51.04 Mill € | 0 | 0.00 Mill € |
CIN 2/3 | 15,285 | 35.50 Mill € | 27,648 | 64.22 Mill € | 12,363 | 28.72 Mill € |
VIN2/3 | 1001 | 3.93 Mill € | 1162 | 4.56 Mill € | 161 | 0.63 Mill € |
VaIN 2/3 | 155 | 0.55 Mill € | 186 | 0.66 Mill € | 31 | 0.11 Mill € |
AIN 2/3 (b) | 149 | 0.59 Mill € | 162 | 0.65 Mill € | 13 | 0.05 Mill € |
PIN 2/3 | 218 | 0.59 Mill € | 247 | 0.67 Mill € | 29 | 0.08 Mill € |
Cervical cancer (c) | 1730 | 15.15 Mill € | 2110 | 18.48 Mill € | 380 | 3.33 Mill € |
Vulvar cancer (d) | 94 | 1.22 Mill € | 110 | 1.43 Mill € | 16 | 0.21 Mill € |
Vaginal cancer (c) | 50 | 0.54 Mill € | 66 | 0.71 Mill € | 16 | 0.17 Mill € |
Anal cancer (b)(c)(e) | 264 | 2.02 Mill € | 289 | 2.21 Mill € | 25 | 0.19 Mill € |
Penile cancer (c)(e) | 98 | 0.70 Mill € | 111 | 0.79 Mill € | 13 | 0.09 Mill € |
Oral cavity (b)(c)(e) | 131 | 1.03 Mill € | 147 | 1.15 Mill € | 16 | 0.12 Mill € |
Nasopharynx (b)(c)(e) | 27 | 0.21 Mill € | 32 | 0.25 Mill € | 5 | 0.04 Mill € |
Oropharynx cancer (b)(c)(e) | 258 | 1.94 Mill € | 272 | 2.05 Mill € | 14 | 0.10 Mill € |
Hypopharynx (b)(c)(e) | 28 | 0.23 Mill € | 34 | 0.28 Mill € | 6 | 0.05 Mill € |
Pharynx cancer (b)(c)(e) | 39 | 0.30 Mill € | 39 | 0.30 Mill € | 0 | 0.00 Mill € |
Larynx cancer (b)(c)(e) | 132 | 1.15 Mill € | 171 | 1.49 Mill € | 39 | 0.34 Mill € |
TOTAL | 68,910 | 116.7 Mill € | 82,038 | 150.9 Mill € | 13,128 | 34.24 Mill € |